![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: RAPSN |
Gene summary for RAPSN |
![]() |
Gene information | Species | Human | Gene symbol | RAPSN | Gene ID | 5913 |
Gene name | receptor associated protein of the synapse | |
Gene Alias | CMS11 | |
Cytomap | 11p11.2 | |
Gene Type | protein-coding | GO ID | GO:0001941 | UniProtAcc | A0A0S2Z4F8 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
5913 | RAPSN | C06 | Human | Oral cavity | OSCC | 2.11e-03 | 3.32e-01 | 0.2699 |
5913 | RAPSN | C07 | Human | Oral cavity | OSCC | 4.20e-02 | 4.50e-01 | 0.2491 |
5913 | RAPSN | SYSMH5 | Human | Oral cavity | OSCC | 8.75e-05 | 1.82e-01 | 0.0647 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Oral Cavity | ![]() | EOLP: Erosive Oral lichen planus |
LP: leukoplakia | ||
NEOLP: Non-erosive oral lichen planus | ||
OSCC: Oral squamous cell carcinoma |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:009015018 | Oral cavity | OSCC | establishment of protein localization to membrane | 163/7305 | 260/18723 | 7.13e-15 | 4.47e-13 | 163 |
GO:199077816 | Oral cavity | OSCC | protein localization to cell periphery | 190/7305 | 333/18723 | 1.46e-11 | 5.13e-10 | 190 |
GO:007099720 | Oral cavity | OSCC | neuron death | 202/7305 | 361/18723 | 3.75e-11 | 1.23e-09 | 202 |
GO:190121420 | Oral cavity | OSCC | regulation of neuron death | 174/7305 | 319/18723 | 1.09e-08 | 2.23e-07 | 174 |
GO:190121620 | Oral cavity | OSCC | positive regulation of neuron death | 63/7305 | 97/18723 | 2.02e-07 | 3.25e-06 | 63 |
GO:005140217 | Oral cavity | OSCC | neuron apoptotic process | 134/7305 | 246/18723 | 5.65e-07 | 8.19e-06 | 134 |
GO:004352310 | Oral cavity | OSCC | regulation of neuron apoptotic process | 111/7305 | 212/18723 | 5.12e-05 | 4.27e-04 | 111 |
GO:004352518 | Oral cavity | OSCC | positive regulation of neuron apoptotic process | 37/7305 | 58/18723 | 1.15e-04 | 8.35e-04 | 37 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RAPSN | SNV | Missense_Mutation | rs769989407 | c.661N>T | p.Arg221Cys | p.R221C | Q13702 | protein_coding | deleterious(0) | possibly_damaging(0.606) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
RAPSN | SNV | Missense_Mutation | rs529117281 | c.1036N>T | p.Arg346Trp | p.R346W | Q13702 | protein_coding | deleterious(0) | possibly_damaging(0.614) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RAPSN | SNV | Missense_Mutation | rs761584017 | c.493N>A | p.Val165Met | p.V165M | Q13702 | protein_coding | deleterious(0.01) | probably_damaging(0.974) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RAPSN | SNV | Missense_Mutation | novel | c.854N>G | p.Gln285Arg | p.Q285R | Q13702 | protein_coding | deleterious(0.03) | benign(0.001) | TCGA-AJ-A3BG-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | PD |
RAPSN | SNV | Missense_Mutation | rs761584017 | c.493N>A | p.Val165Met | p.V165M | Q13702 | protein_coding | deleterious(0.01) | probably_damaging(0.974) | TCGA-AJ-A3OJ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
RAPSN | SNV | Missense_Mutation | c.926N>A | p.Ile309Asn | p.I309N | Q13702 | protein_coding | tolerated(0.4) | benign(0.003) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
RAPSN | SNV | Missense_Mutation | novel | c.413N>C | p.Val138Ala | p.V138A | Q13702 | protein_coding | tolerated(0.84) | benign(0) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
RAPSN | SNV | Missense_Mutation | rs777749381 | c.53N>G | p.Gln18Arg | p.Q18R | Q13702 | protein_coding | deleterious(0.01) | benign(0.137) | TCGA-AX-A2HJ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RAPSN | SNV | Missense_Mutation | c.632A>G | p.His211Arg | p.H211R | Q13702 | protein_coding | deleterious(0.03) | benign(0.403) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
RAPSN | SNV | Missense_Mutation | novel | c.1018N>T | p.Gly340Trp | p.G340W | Q13702 | protein_coding | deleterious(0) | probably_damaging(0.938) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |